E-viri
PDF
Recenzirano
Odprti dostop
-
De Backer, Ole; Dangas, George D; Jilaihawi, Hasan; Leipsic, Jonathon A; Terkelsen, Christian J; Makkar, Raj; Kini, Annapoorna S; Veien, Karsten T; Abdel-Wahab, Mohamed; Kim, Won-Keun; Balan, Prakash; Van Mieghem, Nicolas; Mathiassen, Ole N; Jeger, Raban V; Arnold, Martin; Mehran, Roxana; Guimarães, Ana H.C; Nørgaard, Bjarne L; Kofoed, Klaus F; Blanke, Philipp; Windecker, Stephan; Søndergaard, Lars
The New England journal of medicine, 01/2020, Letnik: 382, Številka: 2Journal Article
In a trial, patients who had undergone successful TAVR were assigned to rivaroxaban or antiplatelet therapy. In this substudy in patients who underwent CT, leaflet thickening and reduced leaflet motion at 90 days were less common with rivaroxaban. However, in the main trial, rivaroxaban was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding.
